Mitiglinide Calcium Capsules The new version of the medical insurance catalog of clinical application advantages of analysis


xq
 
Early-phase insulin secretion defect is a characteristic manifestation of abnormal insulin secretion pattern in type 2 diabetes mellitus patients, and insulinotropic agents have an important role in the treatment of type 2 diabetes mellitus. Coinciding with the successful entry of the new mealtime insulinotropic agent, Miglinide calcium, into the new version of the national health insurance catalog, Diabetes International invited Prof. Mou Yiming of the General Hospital of the Chinese People's Liberation Army to explain the advantages of the application and the applicable population of Miglinide calcium, and to analyze the benefits that will be provided to the patients after its entry into the health insurance.
 

Importance of early phase insulin secretion in human glucose regulation
 
The rapid secretion of insulin is important in the body during any meal state because it rapidly converts glucose into glycogen to be stored as energy in the liver, avoiding blood glucose spikes in the blood. Impaired early-phase insulin secretion is an important marker in the gradual transition from prediabetes to diabetes.

Mitiglinide Calcium Reduces Postprandial Glucose While Avoiding Hypoglycemia
 
The sudden rise in blood glucose after a meal is one of the most important pathophysiologic changes leading to postprandial hyperglycemia and postprandial hyperinsulinemia. The new insulinotropic agent Miglinide calcium, as a mealtime insulinotropic agent, is more specific to postprandial hyperglycemia than other glucagonists, including Repaglinide, and has a very rapid onset of action. It only needs to be taken 5 minutes before a meal, and the peak effect can be reached in 15-20 minutes. This time point precisely matches the peak of blood glucose elevation after a meal, enabling insulin to closely match the rapid increase in blood glucose, and allowing insulin to be secreted quickly to bring blood glucose down as soon as blood glucose rises. By bringing the blood sugar down at this point, there is no insulin spike about 2 hours after the meal to cause hypoglycemia before the next meal. Therefore, Miglinide Calcium is not only effective in controlling diabetes, especially postprandial hyperglycemia, but it is also very safe, easy to use, and has a very low incidence of hypoglycemia.
 
People with Miglinide Calcium

Miglinide calcium is fast-acting, fast-acting, and very effective in lowering postprandial blood glucose, as well as avoiding hypoglycemia caused by excessive drop in blood glucose. Because of its short duration of action, it only targets the adjustment of blood glucose at meal time, so it is suitable for all patients with type 2 diabetes with some pancreatic islet function, especially those who have predominantly postprandial blood glucose increase. Moreover, the unique metabolic pathway of Miglinide, which does not rely on hepatic P450 enzyme metabolism, makes it less risky for drug-drug interactions, making the use of Miglinide Calcium safer and more potent than other prokinetic agents, with less risk of hypoglycemia, in older adults who have relatively poor pancreatic islet function and ability to self-help and who tend to be comorbid with other chronic diseases.
 

Analysis of the reasons for the inclusion of mignonide calcium in the medical insurance catalog
 
In the section of diabetes treatment drugs, the purpose of the National Health Insurance Catalog is to enable diabetic patients to have access to more effective, safe and scientific treatments. Miglinide calcium has been on the market for many years, and has gained a lot of research evidence in China and internationally, which has also made clinicians realize that it is more effective in lowering postprandial blood glucose as a glucose-lowering drug, with less risk of hypoglycemia. The inclusion of this drug in the national health insurance catalog is a boon to patients and gives doctors more and better tools to treat diabetes. After the entry of Miglinide calcium into the medical insurance catalog, it will surely play a great role in many diabetic patients, especially the elderly patients who are suitable for the application of this kind of drug, which is mainly used for postprandial blood glucose increase, and it will also bring more benefits, more convenient and safer to many patients.
 
  (Source: Diabetes International Editorial Board)

Other Dynamics


Mitiglinide Calcium Capsules The new version of the medical insurance catalog of clinical application advantages of analysis

Early-phase insulin secretion defect is a characteristic manifestation of abnormal insulin secretion pattern in type 2 diabetes mellitus patients, and insulinotropic agents have an important role in the treatment of type 2 diabetes mellitus. Coinciding with the successful entry of the new mealtime insulinotropic agent, Miglinide calcium, into the new version of the national health insurance catalog, Diabetes International invited Prof. Mou Yiming of the General Hospital of the Chinese People's Liberation Army to explain the advantages of the application and the applicable population of Miglinide calcium, and to analyze the benefits that will be provided to the patients after its entry into the health insurance.


Explanation of pharmacological effects of Miglinide calcium in the new version of the medical insurance catalog

Defective β-cell insulin secretion is one of the central aspects of the pathogenesis of type 2 diabetes. Coinciding with the successful entry of the new mealtime insulinotropic agent, Miglinide calcium, into the new version of the National Health Insurance Catalog, Diabetes International invited Prof. Zhigang Zhao of the Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, to make a professional analysis of the advantages of the action of the new insulinotropic agent from the perspective of pharmacology.


Effective reduction of postprandial hyperglycemia preferred medication - Miglinide calcium capsule

What's worse, the probability of diabetes is increasing among people under the age of 40, as well as pregnant women, and even primary and secondary school students in China.


Golden single product, the heart and brain with treatment - Yixinone dispersible tablets

According to the World Health Organization: the number of people suffering from cardiovascular disease in China has reached 300 million, i.e. 2 out of every 10 adults suffer from cardiovascular disease.


Pioglitazone is the preferred drug for the treatment of type 2 diabetes mellitus.

Diabetes mellitus is a disorder of sugar, fat and protein metabolism caused by a defect in insulin secretion or a decrease in the sensitivity of body tissues and cells to insulin. It is characterized by high blood glucose and is often characterized by excessive urination, drinking, eating and wasting, i.e. "three more and one less".


Drug procurement "national first standard" came drug companies or face different situations

On November 15, the full text of the "4+7" Cities Drug Centralized Purchasing Document was published. With the consent of the Central Committee for Comprehensively Deepening Reform, the State organized a pilot centralized procurement of medicines, and the scope of the pilot area is Beijing, Tianjin, Shanghai, Chongqing, as well as Shenyang, Dalian, Xiamen, Guangzhou, Shenzhen, Chengdu, Xi'an, and other 11 cities (referred to as the "4 + 7 cities"). According to the procurement documents, the first batch of banded procurement catalog totaled 31 varieties, including cefuroxime tablets, escitalopram oxalate tablets, and resuvastatin calcium tablets that have been full of three enterprises through consistency evaluation.